MVRBF Stock UPDATES Medivir Ser B Sek5 (MVRBF) 18.2900 08/03/2014

New Post Public Reply Private Reply Replies (0) Message Board

Aug 3, 2014 at 4:51 AM

Medivir Ser B Sek5 (MVRBF) 18.2900 $MVRBF

Medivir: Phase II COSMOS Study Results Published in The Lancet on World Hepatitis Day
Business Wire - Mon Jul 28, 1:41AM CDT
Regulatory News:

Medivir reports global net sales of USD831m for Olysio during Q2 2014
M2 - Wed Jul 16, 3:38AM CDT
Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced on Tuesday that the global second quarter 2014 net sales of Olysio (simeprevir) amounted to USD831m, out of which USD725m were sales in the US.

Medivir: U.S. FDA Has Granted Priority Review for OLYSIO(R) in Combination with sofosbuvir Supplementary New Drug Application
Business Wire - Tue Jul 15, 8:41AM CDT
Medivir (STO:MVIR-

Medivir: Continued strong market uptake for OLYSIO(R) during the second quarter 2014
Business Wire - Tue Jul 15, 7:11AM CDT
Regulatory News:

Medivir's OLYSIO to be available soon in all Nordic countries
M2 - Tue Jun 10, 8:00AM CDT
Medivir AB (OMX: MVIR), a research-based pharmaceutical company, announced today the availability of Olysio in all of the Nordic countries within the next few weeks for the treatment of adults with hepatitis C genotype 1 and 4 infection.

Medivir: OLYSIO(TM) available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection
Business Wire - Tue Jun 10, 1:44AM CDT
Regulatory News:

Osteoarthritis - Pipeline Review, H1 2014: Includes 50 Company Profiles
M2 - Thu May 29, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j5kb3t/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. The report features investigatory drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Scope - The report provides a snapshot of the global therapeutic landscape of Osteoarthritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Mentioned: - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Abiogen Pharma S.p.A. - Ablynx NV - AcurePharma AB - Addex Therapeutics - Allinky Biopharma - Ampio Pharmaceuticals, Inc. - Amura Holdings Ltd. - Asahi Kasei Pharma Corp. - Asklepios BioPharmaceutical, Inc. - Astellas Pharma Inc. - Aurigene Discovery Technologies Limited - Biopharm GmbH - Bone Medical Limited - Calzada Limited - Can-Fite BioPharma Ltd. - Cellceutix Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Chugai Pharmaceutical Co., Ltd. - CrystalGenomics, Inc. - Galapagos NV - Genequine Biotherapeutics GmbH - Janssen Biotech, Inc. - Jenrin Discovery, Inc. - Laila Pharmaceuticals Pvt. Ltd. - MediPost Co., Ltd. - Medivir AB - Merck KGaA For more information visit http://www.researchandmarkets.com/research/j5...oarthritis

Medivir's Simeprevir approved for treatment in Russia
M2 - Mon Mar 24, 5:26AM CDT
Medivir AB (STO:MVIRB.ST), a research-based pharmaceutical company focused on infectious diseases, announced today the approval by the Russian Ministry of Health of Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.

Medivir: New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)
Business Wire - Mon Mar 24, 4:48AM CDT
Regulatory News:

Medivir: Simeprevir has now been approved in Russia
Business Wire - Mon Mar 24, 2:40AM CDT
Regulatory News:

Medivir: The Nomination Committee's Proposal, with Reference to the Upcoming 2014 Annual General Meeting, for a New Board of Directors
Business Wire - Fri Mar 14, 7:43AM CDT
Regulatory News:

Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented
Business Wire - Tue Mar 04, 11:30AM CST
Regulatory News:

Medivir reports profit in 2013
M2 - Mon Feb 24, 6:37AM CST
Swedish medical research company Medivir AB (STO:MVIRB.ST) reported today profit after tax of SEK16m, or SEK 0.51 per share, for the year 2013, from 1 January 2013 to 31 December 2013.

Swedish Pharmaceutical Company Medivir AB Chooses Certara's D360 as Its Global Drug Discovery Platform
Business Wire - Mon Jan 27, 7:00AM CST
Certara(TM), a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Medivir AB, a Swedish pharmaceutical company that focuses on infectious diseases including hepatitis C, has selected D360 as its global drug discovery platform. Certara's D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. Medivir will use D360 to deliver research data and analytic tools to its discovery chemists and biologists in Stockholm, Sweden, and Cambridge, UK. The information will be sourced from its existing repository of chemical structure and biological assay data.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Breaking Down Oklahoma's Car Insurance Costs

Understanding Car Insurance Dynamics in Oklahoma In the labyrinth of car insurance premiums, drivers in Oklahoma are left navigating a multitude of factors. A recent article from HelloNation, featuring insurance agent Bobby Williamson, dives into these elements with a candor that cuts through the fluff. Understanding what drives those numbers up or down isn't just for the...

Johnson Controls FY26 Results Highlight Growth Momentum

Unpacking Johnson Controls' Fiscal 2026 Performance You know, it's not often that a company hits a home run with back-to-back quarters, but Johnson Controls (NYSE:JCI) seems to be swinging for the fences as they wrap up fiscal 2026. What we've got here is a robust set of financial results, showcasing not just growth but momentum that's got investors humming. We're talking...

Metropolitan at The 9 Unveils Major Renovation in 2026

A Cleveland Gem Gets a Makeover Alright, listen up—Metropolitan at The 9 in Cleveland has undergone a massive facelift. We're talking about a complete overhaul of every single one of its 156 guestrooms and suites, new elevators, a refreshed lobby, and a reimagined Ledger Bar. Details and Delights in Every Corner Let's dig into the nitty-gritty. Guests are walking into...

Classet and Reelist Revamp Frontline Hiring Methods

Social Media's New Role in Hiring Who'd have thought? Scrolling through cat videos now lands you a job interview. The partnership between Classet and Reelist has thrown the hiring game a curveball, offering a seamless ride from a hashtagged post to a phone chat with an AI recruiter named Joy—and all in record time. For those looking to hire frontline or skilled trades...

Shrieve Expands with Clear Solutions Takeover

Strategic Acquisition with Environmental Edge Who'd have thought Shrieve Chemical and Clear Solutions would hitch their wagons? This move, caught from the windy plains of Texas to the greens of Shrewsbury, has all the makings of a sharp strategic pairing. Shrieve Chemical, backed by Gemspring Capital, has swallowed UK-based Clear Solutions, a feisty name in water-based...

Implantica's Strategic U.S. Entry with RefluxStop®

Implantica's Ambitious Move into the U.S. Market Every now and then, a move in the medtech sector grabs everyone's attention, and that's what we got with Implantica's latest play. This company is pulling out the big guns to push its RefluxStop® device into the U.S. market—one of the toughest nuts to crack. They've roped in Dr. John C. Lipham, a leading U.S. surgeon, to...

Revamp Preschool Questions for Richer Conversations

Preschoolers, those tiny agents of chaos, come home with stories that you'd need a magnifying glass to find. Ask 'em "How was school?" and you're met with blank stares or a one-liner. Tami Nix of Archway Academy has been at this game for over 40 years, and she's got a trick or six up her sleeve. Ditch the Generic: Get Specific Yep, those generic questions are about as...

DIRECTV and DAZN: NBA Games Reach Local Fans

DIRECTV Teams Up With DAZN: A Slam Dunk for NBA Fans DIRECTV just inked a deal with DAZN to broadcast games for five NBA teams—Cleveland Cavaliers, Indiana Pacers, Memphis Grizzlies, Minnesota Timberwolves, and San Antonio Spurs—across their territories. For fans, this means a whole lot more hoops action conveniently bundled into your TV package, right in your living...

Alfa Laval's Earnings Rise Despite Soft Q4 Outlook

Understanding Alfa Laval's Third Quarter Surge Alfa Laval's third quarter report isn't just another financial document; it's a reflection of the volatility and unpredictable nature of the engineering sector. Sure, revenues and earnings have shot up, but there's a hint of caution as we steer into the fourth quarter. Order intake—a term that gives every investor a reason...

Epson Innovates Order Pickup at Florida Food Hall

Changing the Food Hall Game Innovation isn't just a Silicon Valley buzzword; it found its place at the Central Park St. Pete Food Hall in Florida. These guys have figured out the magic formula to streamline multi-vendor dining with Epson's point-of-sale label printers. We're talking about keeping guests from playing musical chairs with food orders, folks. It's a...